{"id":"placebo-in-addition-to-udca-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"Placebo does not have a known mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:44.836Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary biliary cholangitis"}]},"trialDetails":[{"nctId":"NCT07477782","phase":"PHASE2","title":"Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05","conditions":"Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)","enrollment":72},{"nctId":"NCT07457632","phase":"PHASE2","title":"Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine.","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":69},{"nctId":"NCT07424677","phase":"PHASE3","title":"Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy","status":"NOT_YET_RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2026-03","conditions":"Primary Biliary Cholangitis","enrollment":89},{"nctId":"NCT04594694","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2019-10-02","conditions":"Primary Biliary Cholangitis","enrollment":75},{"nctId":"NCT06247735","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kowa Research Institute, Inc.","startDate":"2024-02-07","conditions":"Primary Biliary Cholangitis","enrollment":46},{"nctId":"NCT06443606","phase":"PHASE3","title":"Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-27","conditions":"BPC, Non Optimal Response to UDCA","enrollment":108},{"nctId":"NCT06294847","phase":"PHASE3","title":"Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2024-08-20","conditions":"Retinal Detachment","enrollment":120},{"nctId":"NCT06026865","phase":"NA","title":"S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2023-08-01","conditions":"Primary Sclerosing Cholangitis (PSC)","enrollment":60},{"nctId":"NCT05450887","phase":"PHASE3","title":"Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2021-09-23","conditions":"Primary Biliary Cholangitis","enrollment":108},{"nctId":"NCT05973370","phase":"PHASE2","title":"Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-05-01","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05416580","phase":"PHASE3","title":"Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Banja Luka","startDate":"2022-09-12","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT04834557","phase":"PHASE2","title":"Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-11-01","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT01654731","phase":"PHASE3","title":"Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10-15","conditions":"PBC","enrollment":100},{"nctId":"NCT04309773","phase":"PHASE3","title":"Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-06","conditions":"Primary Sclerosing Cholangitis, Cholestasis","enrollment":104},{"nctId":"NCT04937023","phase":"NA","title":"Ursodeoxycholic Acid (Udca) as a Local Drug Delivery Agent in the Treatment of Intra-bony Defects","status":"UNKNOWN","sponsor":"SVS Institute of Dental Sciences","startDate":"2021-06-11","conditions":"Bone Regeneration","enrollment":26},{"nctId":"NCT00746486","phase":"PHASE3","title":"Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2009-02","conditions":"Primary Biliary Cirrhosis","enrollment":62},{"nctId":"NCT03124108","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Genfit","startDate":"2017-04-05","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":45},{"nctId":"NCT02033876","phase":"PHASE2","title":"Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-10","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT03668145","phase":"NA","title":"Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2017-11-08","conditions":"Primary Biliary Cirrhosis","enrollment":140},{"nctId":"NCT02319629","phase":"NA","title":"Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2014-12","conditions":"Morbid Obesity","enrollment":266},{"nctId":"NCT01899703","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-10","conditions":"Cholestasis, Intrahepatic","enrollment":22},{"nctId":"NCT02721862","phase":"PHASE3","title":"Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2016-03","conditions":"Cholelithiasis","enrollment":100},{"nctId":"NCT00805805","phase":"PHASE3","title":"Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"George Brewer","startDate":"2006-04","conditions":"Primary Biliary Cirrhosis","enrollment":29},{"nctId":"NCT01483248","phase":"PHASE1, PHASE2","title":"Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis","status":"UNKNOWN","sponsor":"S-Evans Biosciences Co., Ltd.","startDate":"2010-10","conditions":"Liver Cirrhosis, Fibrosis, Liver Disease","enrollment":50},{"nctId":"NCT01141322","phase":"PHASE4","title":"Cholestatic Drug-induced Liver Injury","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2007-08","conditions":"Hepatitis, Toxic","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo in addition to UDCA therapy","genericName":"Placebo in addition to UDCA therapy","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo does not have a known mechanism of action. Used for Primary biliary cholangitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}